Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation
Background Evidence on maintenance therapy following frontline induction is sparse in primary light-chain amyloidosis (AL), especially for those who do not undergo autologous haematopoietic stem cell transplantation (ASCT).Methods We enrolled primary AL patients who achieved at least haematologic ve...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2024.2418339 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181295848554496 |
|---|---|
| author | Wenjing Wang Jing Li Tianhong Xu Yang Yang Chenqi Yu Pu Wang Chi Zhou Peng Liu |
| author_facet | Wenjing Wang Jing Li Tianhong Xu Yang Yang Chenqi Yu Pu Wang Chi Zhou Peng Liu |
| author_sort | Wenjing Wang |
| collection | DOAJ |
| description | Background Evidence on maintenance therapy following frontline induction is sparse in primary light-chain amyloidosis (AL), especially for those who do not undergo autologous haematopoietic stem cell transplantation (ASCT).Methods We enrolled primary AL patients who achieved at least haematologic very good partial response (VGPR) by the 4th month at the frontline from December 2008 to June 2023 at Zhongshan Hospital, Fudan University. Those who followed maintenance therapy were identified as the maintenance group (n = 44), whereas those entering the observational phase were classified as the observational group (n = 24).Results After 7.2(interquartile range, 4.7–18.6) months of maintenance therapy, 9(20.5%), 14(31.8%) and 5 (11.4%) patients achieved improvement in haematologic, cardiac and renal response respectively. Five (11.4%) patients had minimal residual disease (MRD) response conversion from positive to negative based on maintenance therapy. In the observation group, none of the patients had haematologic response improvement, with 3(12.5%) and 1(4.2%) patient showing cardiac and renal response improvement during follow-up.Conclusion This study identified the clinical benefits of maintenance therapy in patients with AL who did not undergo ASCT in real-world practice. |
| format | Article |
| id | doaj-art-20d21c08dd2f4e4aaab09c5dd05aa942 |
| institution | OA Journals |
| issn | 0785-3890 1365-2060 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj-art-20d21c08dd2f4e4aaab09c5dd05aa9422025-08-20T02:17:57ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602024-12-0156110.1080/07853890.2024.2418339Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantationWenjing Wang0Jing Li1Tianhong Xu2Yang Yang3Chenqi Yu4Pu Wang5Chi Zhou6Peng Liu7Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, ChinaBackground Evidence on maintenance therapy following frontline induction is sparse in primary light-chain amyloidosis (AL), especially for those who do not undergo autologous haematopoietic stem cell transplantation (ASCT).Methods We enrolled primary AL patients who achieved at least haematologic very good partial response (VGPR) by the 4th month at the frontline from December 2008 to June 2023 at Zhongshan Hospital, Fudan University. Those who followed maintenance therapy were identified as the maintenance group (n = 44), whereas those entering the observational phase were classified as the observational group (n = 24).Results After 7.2(interquartile range, 4.7–18.6) months of maintenance therapy, 9(20.5%), 14(31.8%) and 5 (11.4%) patients achieved improvement in haematologic, cardiac and renal response respectively. Five (11.4%) patients had minimal residual disease (MRD) response conversion from positive to negative based on maintenance therapy. In the observation group, none of the patients had haematologic response improvement, with 3(12.5%) and 1(4.2%) patient showing cardiac and renal response improvement during follow-up.Conclusion This study identified the clinical benefits of maintenance therapy in patients with AL who did not undergo ASCT in real-world practice.https://www.tandfonline.com/doi/10.1080/07853890.2024.2418339Hematologic responselight chain amyloidosismaintenance therapyminimal residual diseaseorgan response |
| spellingShingle | Wenjing Wang Jing Li Tianhong Xu Yang Yang Chenqi Yu Pu Wang Chi Zhou Peng Liu Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation Annals of Medicine Hematologic response light chain amyloidosis maintenance therapy minimal residual disease organ response |
| title | Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation |
| title_full | Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation |
| title_fullStr | Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation |
| title_full_unstemmed | Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation |
| title_short | Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation |
| title_sort | maintenance therapy promotes profound organ and haematologic response in light chain amyloidosis patients not undergoing autologous stem cell transplantation |
| topic | Hematologic response light chain amyloidosis maintenance therapy minimal residual disease organ response |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2024.2418339 |
| work_keys_str_mv | AT wenjingwang maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation AT jingli maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation AT tianhongxu maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation AT yangyang maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation AT chenqiyu maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation AT puwang maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation AT chizhou maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation AT pengliu maintenancetherapypromotesprofoundorganandhaematologicresponseinlightchainamyloidosispatientsnotundergoingautologousstemcelltransplantation |